LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor.

J Oncol · 2021 · PMC8018836 · PMID 33833800

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The Outcome of Some LSD1 Inhibitors in Clinical Trials The role of LSD1 during carcinogenesis is highly significant and targeting LSD1 has become an emerging option for tumor treatment.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.